- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06863272
Une étude clinique des combinaisons de traitement à base d'ifinatamab derropxecan ou en tant que monothérapie pour traiter le cancer de la prostate résistant aux castrates métastatiques (MCRPC) (MK-2400-01A / Ideate-Prostate02)
MK-2400-01A TRUDUDE: Une sous-étude de la phase 1/2, Open Ablabel Subdyd of MK-2400-U01 Master Protocol pour évaluer la sécurité et l'efficacité de l'ifinatamab Deruxecan Basy Combinations ou Ifinatamab Deruxcan seul chez les participants avec un cancer de la castation métastatique) (MCRPC) (mcreate-protation-résistant Cancer du prostate (MCRE
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
- The safety of the study treatment and if people tolerate it.
- A safe dose level of I-DXd that can be used with other treatments.
- Participant levels of prostate specific antigen (PSA) during treatment.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This sub study MK-2400-01A assesses treatments for metastatic castration-resistant prostate cancer (mCRPC).
The master screening protocol is MK-2400-U01
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Toll Free Number
- Numéro de téléphone: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lieux d'étude
-
-
-
Hamburg, Allemagne, 20246
- Recrutement
- Universitaetsklinikum Hamburg-Eppendorf ( Site 0524)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +4915222815585
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Allemagne, 69120
- Recrutement
- NCT ( Site 0528)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 00496221566857
-
Ulm, Baden-Wurttemberg, Allemagne, 89081
- Recrutement
- Universitaetsklinikum Ulm. ( Site 0530)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +4973150058188
-
-
Thuringia
-
Jena, Thuringia, Allemagne, 07747
- Recrutement
- Universitaetsklinikum Jena ( Site 0525)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +49-3641-9-329901
-
-
-
-
-
La Rioja, Argentine, F5300COE
- Recrutement
- Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 54-380-443-6443
-
-
Buenos Aires
-
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentine, C1426ANZ
- Recrutement
- Instituto Alexander Fleming ( Site 0202)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 5411 3221 8900
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australie, 2109
- Recrutement
- Macquarie University-MQ Health Clinical Trials Unit ( Site 0801)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +61 2 9812 2956
-
-
-
-
-
São Paulo, Brésil, 01221-020
- Recrutement
- IPITEC ( Site 0275)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +551194322-6006
-
São Paulo, Brésil, 03102-006
- Recrutement
- IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +551144500360
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brésil, 59062-000
- Recrutement
- Liga Norte Riograndense Contra o Câncer ( Site 0271)
-
Contact:
- Study Coordinator
- Numéro de téléphone: (84) 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90035-001
- Recrutement
- Hospital Moinhos de Vento ( Site 0278)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +55 51 3314-3209
-
Porto Alegre, Rio Grande do Sul, Brésil, 90020-090
- Recrutement
- Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +555132148151
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brésil, 12916-542
- Recrutement
- Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0268)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +551124901366
-
Ribeirão Preto, São Paulo, Brésil, 14048900
- Recrutement
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) ( Site 0273)
-
Contact:
- Study Coordinator
- Numéro de téléphone: (16) 3963-6487
-
São José do Rio Preto, São Paulo, Brésil, 15090-000
- Recrutement
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +55 17 99625-3919
-
São Paulo, São Paulo, Brésil, 01327-001
- Recrutement
- Hospital Alemao Oswaldo Cruz ( Site 0279)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 55 11 3549-0009
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Recrutement
- BC Cancer - Vancouver Center ( Site 0103)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 6048776000
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Recrutement
- Sunnybrook Research Institute ( Site 0109)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 4164806100
-
Toronto, Ontario, Canada, M5G 2M9
- Recrutement
- Princess Margaret Cancer Centre ( Site 0102)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 4169464501
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recrutement
- Jewish General Hospital ( Site 0108)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 5143408110
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recrutement
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0107)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 8197802222
-
-
-
-
Maule Region
-
Talca, Maule Region, Chili, 3465584
- Recrutement
- Clinica Universidad Catolica del Maule ( Site 0236)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 56992992913
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chili, 8420383
- Recrutement
- Bradfordhill ( Site 0231)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +56229490970
-
Santiago, Region M. de Santiago, Chili, 7560908
- Recrutement
- Centro de Oncología de Precisión ( Site 0241)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +56225189885
-
Santiago, Region M. de Santiago, Chili, 7500921
- Recrutement
- Fundación Arturo López Pérez ( Site 0232)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 56224205098
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chili, 2520598
- Recrutement
- ONCOCENTRO APYS ( Site 0234)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +56323320850
-
-
-
-
-
Seoul, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center ( Site 0926)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82234103459
-
Seoul, Corée du Sud, 03722
- Actif, ne recrute pas
- Severance Hospital Yonsei University Health System ( Site 0924)
-
-
Seoul
-
Songpagu, Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center ( Site 0925)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82230105977
-
-
-
-
-
Madrid, Espagne, 28034
- Recrutement
- Hospital Universitario Ramon y Cajal ( Site 0620)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34913368263
-
Madrid, Espagne, 28041
- Recrutement
- Hospital Universitario 12 de Octubre ( Site 0622)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34608464547
-
Madrid, Espagne, 28040
- Recrutement
- Hospital Clinico San Carlos ( Site 0618)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34913303546
-
Seville, Espagne, 41013
- Recrutement
- Hospital Universitario Virgen del Rocio ( Site 0619)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34955013068
-
-
Barcelona
-
L Hospitalet Del Llobregat, Barcelona, Espagne, 08908
- Recrutement
- ICO L Hospitalet ( Site 0617)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34932607744
-
-
-
-
Gironde
-
Bordeaux, Gironde, France, 33000
- Recrutement
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 0498)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +33556333261
-
-
Nord
-
Lille, Nord, France, 59000
- Recrutement
- Centre Oscar Lambret ( Site 0495)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +333 20 29 56 06
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, France, 44800
- Recrutement
- Institut De Cancerologie De L Ouest ( Site 0494)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +33240679900
-
-
Pyrenees-Atlantiques
-
Bayonne, Pyrenees-Atlantiques, France, 64100
- Recrutement
- Centre Hospitalier de la Cote Basque ( Site 0496)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +33559443762
-
-
Rhone
-
Pierre-Bénite, Rhone, France, 69310
- Recrutement
- centre hospitalier lyon sud ( Site 0497)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 33 4 78 86 43 24
-
-
-
-
-
Dublin, Irlande, D09 V2N0
- Recrutement
- Beaumont Hospital, Dublin ( Site 0465)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 0035318092010
-
Dublin, Irlande, D24 NR0A
- Recrutement
- Tallaght University Hospital ( Site 0462)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 0035314144209
-
-
Dublin
-
Dublin, Dublin, Irlande, D04 T6F4
- Recrutement
- St Vincent's University Hospital ( Site 0463)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +353 1 221 4982
-
-
-
-
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Health Care Campus ( Site 0400)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 972(47776234)
-
Jerusalem, Israël, 9112001
- Recrutement
- Hadassah Medical Center ( Site 0404)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +97226777333
-
Petah Tikva, Israël, 4941492
- Recrutement
- Rabin Medical Center ( Site 0402)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +972544594048
-
Ramat Gan, Israël, 5265601
- Recrutement
- Sheba Medical Center ( Site 0401)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +97235303030
-
Tel Aviv, Israël, 6423906
- Recrutement
- Sourasky Medical Center ( Site 0403)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +97236947832
-
-
-
-
-
Brescia, Italie, 25123
- Actif, ne recrute pas
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432)
-
Milan, Italie, 20133
- Recrutement
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +390223904449
-
Naples, Italie, 80131
- Recrutement
- A.O.U. Federico II di Napoli ( Site 0435)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +390817463660
-
Roma, Italie, 00168
- Recrutement
- Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +390630155202
-
-
Torino
-
Orbassano, Torino, Italie, 10143
- Recrutement
- AOU San Luigi Gonzaga di Orbassano ( Site 0434)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 00390119026534
-
-
-
-
-
Auckland, Nouvelle-Zélande, 1023
- Recrutement
- Auckland City Hospital ( Site 0831)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +6493074949
-
-
-
-
Gelderland
-
Ede, Gelderland, Pays-Bas, 6716 RP
- Recrutement
- Ziekenhuis Gelderse Vallei ( Site 0683)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +31 318 435499
-
Nijmegen, Gelderland, Pays-Bas, 6525 GA
- Recrutement
- UMC St. Radboud ( Site 0679)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +31 24 361 1111
-
-
Provincie Friesland
-
Drachten, Provincie Friesland, Pays-Bas, 9202 NN
- Recrutement
- Nij Smellinghe ( Site 0684)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 0512 588 888
-
-
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Pologne, 60-355
- Recrutement
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +61 854 79 87
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Pologne, 02-781
- Recrutement
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +48 22 546 33 81
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Pologne, 80-214
- Recrutement
- Uniwersyteckie Centrum Kliniczne ( Site 0588)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +48 58 584 44 66
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Pologne, 75-581
- Recrutement
- Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +48943488930
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Royaume-Uni, CB2 2QQ
- Recrutement
- Addenbrooke's Hospital ( Site 0747)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 00441223216083
-
-
London, City of
-
London, London, City of, Royaume-Uni, NW3 2QG
- Recrutement
- Royal Free Hospital ( Site 0743)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 00442077940500/2237
-
London, London, City of, Royaume-Uni, EC1A 7BE
- Recrutement
- St Bartholomew's Hospital ( Site 0749)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 00442073777000
-
-
Surrey
-
London, Surrey, Royaume-Uni, SM3 5PT
- Recrutement
- Royal Marsden Hospital (Sutton) ( Site 0741)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 0203 437 3500
-
-
-
-
-
Taichung, Taïwan, 40705
- Recrutement
- Taichung Veterans General Hospital ( Site 0902)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +886423592525
-
Taipei, Taïwan, 11217
- Recrutement
- Taipei Veterans General Hospital ( Site 0901)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +886228712121
-
-
-
-
-
Adana, Turquie (Türkiye), 01250
- Recrutement
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0650)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +903223271274
-
Ankara, Turquie (Türkiye), 06230
- Recrutement
- Hacettepe Universitesi Tip Fakultesi ( Site 0648)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +90 312 305 50 00
-
Ankara, Turquie (Türkiye), 06800
- Recrutement
- Ankara Bilkent Şehir Hastanesi ( Site 0654)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +903125526000
-
Ankara, Turquie (Türkiye), 06620
- Recrutement
- Ankara Universitesi Tip Fakultesi Hastanesi ( Site 0653)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +903122126040
-
Istanbul, Turquie (Türkiye), 34010
- Recrutement
- Koç Üniversitesi Hastanesi ( Site 0656)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +905369410661
-
Istanbul, Turquie (Türkiye), 34098
- Recrutement
- Istanbul Universitesi Cerrahpasa ( Site 0649)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +902124143000
-
Rize, Turquie (Türkiye), 53020
- Recrutement
- Recep Tayyip Erdogan University Training and Research Hospital ( Site 0655)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +904642130491
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- UCLA Hematology & Oncology ( Site 0003)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 310-829-5471
-
Orange, California, États-Unis, 92868
- Recrutement
- University of California-Irvine Medical Center ( Site 0016)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 714-456-5153
-
San Francisco, California, États-Unis, 94158
- Recrutement
- UCSF Medical Center at Mission Bay ( Site 0034)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 415-502-2097
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 202-877-3061
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- University of Michigan ( Site 0021)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 734-936-4000
-
-
New York
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center ( Site 0006)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 347-798-8620
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- Recrutement
- UPMC Hillman Cancer Center ( Site 0014)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 412-647-2811
-
-
Tennessee
-
Germantown, Tennessee, États-Unis, 38138
- Recrutement
- The West Clinic, PLLC dba West Cancer Center ( Site 0005)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 901-683-0055
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- Fred Hutchinson Cancer Center ( Site 0013)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 206-288-1111
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment
- Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation/randomization
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation/randomization
- Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current ILD, clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Uncontrolled or significant cardiovascular disease
- History of pituitary dysfunction
- Poorly controlled diabetes mellitus
- History or current condition of adrenal insufficiency (eg, Addison's disease)
- Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).
- Chronic steroid treatment (dose of >10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections
- Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of allogeneic tissue/solid organ transplant
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Docetaxel
Participants will receive docetaxel at a determined dose every 3 weeks (Q3W) for a maximum of 10 cycles. Each cycle is 21 days. |
Administered via Intravenous (IV) infusion at a specified dose on specified days |
|
Expérimental: Ifinatamab Deruxtecan (I-DXd)
Participants will receive I-DXd at a determined dose Q3W until unacceptable toxicity, progressive disease (PD), death or withdrawal of consent. |
Administered via IV infusion at a specified dose on specified days
Autres noms:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. |
|
Expérimental: I-DXd + Opevesostat
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS opevesostat at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Autres noms:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days
Autres noms:
|
|
Expérimental: I-DXd +ARPI (Abiraterone or Enzalutamide)
Following a dose escalation regimen with I-DXd, participants will receive I-DXd at a determined dose until unacceptable toxicity, PD, death or withdrawal of consent PLUS ARPI (Androgen Receptor Pathway Inhibitor) - Abiraterone acetate OR Enzalutamide at a determined dose until any of the criterion for discontinuation of study intervention is met. |
Administered via IV infusion at a specified dose on specified days
Autres noms:
Before each dose of I-DXd, participants are required to take premedication for prevention of nausea and vomiting with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK-1 receptor antagonist as well as other drugs as indicated) per approved product label. Administered orally at a specified dose on specified days Administered orally at a specified dose on specified days |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Délai: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Efficacy Phase: Number of Participants Who Experienced an Adverse Event (AE)
Délai: Up to approximately 54 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 54 months
|
|
Efficacy Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Délai: Up to approximately 24 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 24 months
|
|
Efficacy Phase: Prostate-Specific Antigen (PSA) response rate
Délai: Up to approximately 54 months
|
PSA response is defined per prostate cancer working group (PCWG) criteria as a reduction in the PSA level of 50% or more from baseline measured at consecutive assessments at least 3 weeks apart. |
Up to approximately 54 months
|
|
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Combination Arms Only
Délai: Up to approximately 21 days
|
The following events if considered drug related by the Investigator, will be considered a DLT: Grade 4 nonhematologic toxicity (not based on laboratory value); Grade 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia associated with clinically significant bleeding; Nonhematologic AEs ≥Grade 3 with exceptions; Grade 3 or Grade 4 non-hematologic laboratory values if requires medical intervention, leads to hospitalization, persists for >1 week, or results in a Drug-induced Liver Injury with exceptions; Grade 3 or 4 febrile neutropenia; Study intervention - related toxicities that lead to discontinuation of study treatment during Cycle 1; Prolonged delay (>2 weeks) in initiating Cycles 2 due to treatment-related toxicity; Missing >25% of study intervention doses as a result of treatment-related AE during Cycle 1; Grade 5 toxicity. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE) - Combination Arms Only
Délai: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
|
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE - Combination Arms Only
Délai: Up to approximately 21 days
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 21 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: Up to approximately 54 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per PCWG3-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. |
Up to approximately 54 months
|
|
Radiographic Progression-Free Survival (rPFS)
Délai: Up to approximately 54 months
|
rPFS is defined as the time from randomization to the first documented progressive disease (PD) per PCWG3-modified RECIST 1.1 based on BICR or death due to any cause, whichever occurred first. Per PCWG3-modified RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions or ≥2 new bone lesions was also considered PD. PCWG3-modified RECIST is similar to RECIST 1.1 with the exception that a confirmation assessment of PD (>4 weeks after the initial PD) is required for participants who remain on treatment following a documented PD per RECIST 1.1 and PCWG3 rules include new bone lesions. The rPFS per PCWG3-modified RECIST as assessed by BICR for all participants is presented. The nonparametric Kaplan-Meier method will be used to estimate the rPFS curve in each treatment arm |
Up to approximately 54 months
|
|
Overall Survival (OS)
Délai: Up to approximately 54 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause. The nonparametric Kaplan-Meier method will be used to estimate the survival curves. |
Up to approximately 54 months
|
|
Duration of Response (DOR)
Délai: Up to approximately 54 months
|
DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per PCWG3-modified RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of ≥ 2 new bone lesions is also considered PD. DOR as assessed by BICR is presented. The nonparametric Kaplan-Meier method will be used to estimate the DOR in each treatment arm. |
Up to approximately 54 months
|
|
Time from allocation/randomization to initiation of the first subsequent anticancer therapy (TFST)
Délai: Up to approximately 54 months
|
TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. The nonparametric Kaplan-Meier method will be used to estimate the TFST in each treatment arm. |
Up to approximately 54 months
|
|
Time to Prostate-Specific Antigen (PSA) Progression
Délai: Up to approximately 54 months
|
Time to PSA progression is defined as the time from randomization to PSA progression. Participants without PSA progression will be censored at the last PSA assessment date. The PSA progression date is defined as the date of: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, OR 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. |
Up to approximately 54 months
|
|
Time to pain progression (TTPP)
Délai: Up to approximately 54 months
|
The time from allocation/randomization to pain progression based on the Brief Pain Inventory-Short Form (BPI-SF) Item 3 "worst pain in 24 hours" and by the Analgesic Quantification Algorithm (AQA) score. |
Up to approximately 54 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Medical Director, Merck Sharp & Dohme LLC
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Processus pathologiques
- Tumeurs génitales, homme
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies génitales, sexe masculin
- Maladies de la prostate
- Maladies urogénitales masculines
- Processus néoplasiques
- Conditions pathologiques, signes et symptômes
- Tumeurs prostatiques
- Métastase néoplasmique
- Tumeurs prostatiques, résistantes à la castration
- Produits chimiques organiques
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Taxes
- Cyclodécanes
- Diterpènes
- Docétaxel
- abiraterone
- enzalutamide
Autres numéros d'identification d'étude
- 2400-01A
- MK-2400-01A (Autre identifiant: MSD)
- U1111-1310-5406 (Identificateur de registre: UTN)
- IDeate-Prostate02 (Autre identifiant: MSD)
- 2024-516036-94-00 (Identificateur de registre: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .